NuCana (NCNA)
(Delayed Data from NSDQ)
$6.37 USD
+3.83 (150.79%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $6.12 -0.25 (-3.92%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
NCNA 6.37 +3.83(150.79%)
Will NCNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NCNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NCNA
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
NCNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)
Other News for NCNA
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
Morning Movers: Bausch + Lomb surges as said to consider potential sale
NuCana soars on positive data from mid-stage trial for its melanoma treatment
Oppenheimer Sticks to Their Buy Rating for Nucana (NCNA)